BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2010

View Archived Issues

Clinical data from the evaluation of Debio-025 in HCV-infected patients disclosed

Read More

Recent data support safety and potentcy of HCV NS3 protease inhibitor ACH-1625

Read More

Positive modulators of nAChRalpha7 identified at NeuroSearch

Read More

Roche claims novel gamma-secretase inhibitors

Read More

Snapshots: new reports on biomarkers related to cardiovascular disorders

Read More

Novel tachykinin NK3 receptor antagonists identified at Roche

Read More

Tibotek discloses novel CYP450 inhibitors as boosters for anti-HIV agents

Read More

Novel protein kinase inhibitors presented by Priaxon

Read More

Secreted phospholipase A2 a potential marker of traumatic brain injury

Read More

Intraprostatic botulinum toxin type A improves signs and symptoms of BPH

Read More

Padeliporfin-mediated vascular targeted phototherapy promising in prostate cancer trial

Read More

REDUCE study clarifies effects of dutasteride in prostate cancer

Read More

First quarter events at Chugai

Read More

VaxInnate presents preliminary results from phase II study of VAX-125 flu vaccine

Read More

FDA approves once-daily dosing of Kaletra for previously treated HIV patients

Read More

Prana releases position statement on PBT-2 therapeutic strategy in Alzheimer's disease

Read More

Tarceva receives E.U. approval as maintenance treatment in advanced NSCLC

Read More

Takeda submits NDA for azilsartan medoxomil to treat hypertension in the U.S.

Read More

New biotechnology company, Immunovo, secures seed funding

Read More

New company LipimetiX created to focus on lipid-lowering treatments

Read More

FDA issues complete response letter for Giazo NDA

Read More

PolyMedix initiates phase Ib/II dose-ranging PMX-60056 study

Read More

Ceregene starts new phase I/II study of CERE-120 for Parkinson's disease

Read More

Johns Hopkins and the New York Stem Cell Foundation to collaborate on stem cell research

Read More

Dendreon receives FDA approval for Provenge for castrate-resistant prostate cancer

Read More

NexMed's NexACT technology improves delivery and activity of Angstrom's A6 anticancer compound

Read More

Hana Biosciences completes pre-NDA meeting with FDA for Marqibo

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • China compass

    ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

    BioWorld
    If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Woman taking medication for mental illness

    Autobahn on the fast track with bipolar thyroid agonist

    BioWorld
    Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing